Lifecore Biomedical Inc

Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Maria, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Earnings data Q2 2024

Earnings data Q1 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Lifecore Biomedical explores strategic alternatives and strengthens supply agreements

Lifecore Biomedical's Q3 2023 performance was steady, with strategic strengths in supply agreements and expertise in pharmaceutical injectable-grade HA. However, challenges from timing shifts and inflationary pressures were evident. The company anticipates increased revenue-generating capacity and sees opportunities in expanded supply agreements.

Lifecore Biomedical explores strategic alternatives amidst revenue decline and debt challenges

Lifecore Biomedical's Q2 2023 performance reflects revenue decline, lower gross profit, and challenges from heavy debt burden. The company's strategic review process, led by Morgan Stanley, aims to maximize shareholder value through potential sales or financing transactions. Despite uncertainties leading to the withdrawal of fiscal outlook, Lifecore maintains a proactive stance in addressing operational and financial challenges.

Lifecore Biomedical strengthens partnerships and capacity for future growth

Lifecore Biomedical navigated challenges in Q3 2023 with a focus on strategic partnerships, capacity investments, and a vision for significant revenue growth in the future.
Despite a decrease in financial metrics for the quarter, Lifecore's strengths in CDMO services, development portfolio, and agreements with Alcon position it for long-term success.
Opportunities for growth lie in expanding HA raw material manufacturing, doubling capacity, and leveraging industry trends for revenue expansion in the coming years.

Lifecore Biomedical reports revenue growth and strategic investments for growth

Lifecore Biomedical's Q4 2023 performance showed revenue growth and strategic investments in capacity expansion. While facing challenges in maintaining gross profit margins, the company's focus on CDMO services and development projects presents growth opportunities. Uncertainties surrounding fiscal year 2024 guidance indicate ongoing strategic review processes and potential impacts on future performance.

Lifecore Biomedical reports robust fiscal 2024 performance amidst flat 2025 outlook

Lifecore Biomedical demonstrated strong financial performance in fiscal 2024 with notable revenue and profit increases. While challenges like divestitures impacted the company, strategic measures such as workforce reduction and growth strategies position Lifecore for future success. Opportunities lie in the potential for continued financial growth and revenue generation through targeted strategies.

Lifecore Biomedical reports revenue growth amidst challenges, eyes sustainable growth

Lifecore Biomedical Inc showcased revenue growth and operational improvements in Q1 2025, despite facing a net loss. The company's focus on customer acquisition, expansion, and financial stability presents opportunities for future growth and enhanced performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. It focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The company was founded by Otto Sartorius in 1965 and is headquartered in Chaska, MN.

LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

Investors Are Encouraged By The Schall Law Firm To Participate In A Lawsuit Against Lifecore Biomedical Inc For Securities Fraud

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR).

Lifecore (LFCR) Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Substantial Losses Have the Opportunity to Lead the Action

Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q4 2024 Earnings Conference Call August 27, 2024 8:30 AM ET Company Participants Stephanie Diaz - Vida Strategic Partners, IR Paul Josephs - President & CEO John D. Morberg - CFO & EVP Conference Call Participants Michael Petusky - Barrington Research Operator Greetings, and welcome to the Lifecore Biomedical Q4 and Full Year 2024 Earnings Call.

Lifecore Biomedical, Inc. (LFCR) Q4 2024 Earnings Conference Call Transcript

LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

Lifecore Biomedical Inc Is Being Sued For Possible Securities Law Violations And The Schall Law Firm Invites Shareholders To Assist

-- Recorded Revenues of $128.3 million for Fiscal 2024; Year-Over-Year Increase of 24.2% -- -- High Value Pipeline Continues to Advance Toward Commercialization -- -- State-of-the-Art Technology Enhancements to Expand Capacity and New Business Opportunities –

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update

LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

The Schall Law Firm Is Seeking Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc.

NEW YORK--(BUSINESS WIRE)---- $LFCR--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Minnesota on behalf of those who acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities during the period of October 7, 2020 to March 19, 2024, inclusive (“the Class Period”). Investors have until September 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Cli.

Kirby McInerney LLP Reminds Lifecore Biomedical, Inc. (LFCR) Investors of Class Action Filing and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

Lifecore Biomedical Inc. Is Being Sued For Potential Securities Law Infractions And The Schall Law Firm Invites Shareholder Involvement

NEW YORK CITY, NY / ACCESSWIRE / August 25, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").

LFCR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

A Case Against Lifecore Biomedical Inc For Securities Fraud Has Been Filed And The Schall Law Firm Seeks Investors To Reach Out

Robbins LLP is Investigating Allegations that Lifecore Biomedical, Inc (LFCR) Misled Investors Regarding its Internal Controls Over Financial Reporting

Pending Lead Plaintiff Deadline in the LFCR Class Action: Robbins LLP Reminds Stockholders With Large Losses of Lifecore Biomedical, Inc. to Seek Counsel

LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

Lifecore Biomedical Inc Is Being Sued By The Schall Law Firm For Violations Of Securities Regulations And Stockholders Are Urged To Sign Up

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

Lifecore Biomedical Inc Investors Are Invited By The Schall Law Firm To Participate In A Securities Fraud Lawsuit

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

Shareholders With Losses In Lifecore Biomedical Inc Are Encouraged To Join The Schall Law Firm In A Securities Fraud Suit

LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

The Schall Law Firm Invites Investors To Join In The Securities Fraud Lawsuit Of Lifecore Biomedical Inc Before Sep 27, 2024

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

The Schall Law Firm Encourages Stockholders To Participate In The Lifecore Biomedical Inc Securities Fraud Lawsuit

Shareholder Rights Law Firm Robbins LLP Urges LFCR Stockholders to Contact the Firm for Information About the Lifecore Biomedical, Inc. Class Action

NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

The Schall Law Firm Urges Investors To Join The Lifecore Biomedical Inc Securities Fraud Lawsuit

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

The Schall Law Firm Encourages Shareholders To Take The Lead In The Lifecore Biomedical Inc Securities Fraud Lawsuit

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

The Schall Law Firm Seeks Investors To Take The Lead In The Lifecore Biomedical Inc Securities Fraud Lawsuit

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

The Schall Law Firm Wants Investors To Take The Lead In The Lifecore Biomedical Inc Securities Fraud Lawsuit

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

The Schall Law Firm Encourages Investors To Take The Lead In The Lifecore Biomedical Inc Securities Fraud Lawsuit

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.

ROSEN, A LEADING NATIONAL FIRM, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR

LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

News for Lifecore Biomedical Inc Stock (LFCR)